Roche buys Singapore facility from Lonza

Global healthcare firm Roche, through its subsidiary Genentech, will acquire a Singapore manufacturing facility from Lonza for up to $360 million.

Global healthcare firm Roche will buy a Singapore biologic manufacturing facility for up to $360 million from chemical and biotechnology firm Lonza , the two firms said yesterday.

Basel-based Roche will buy the facility through its San Francisco-headquartered subsidiary Genentech, which it acquired earlier this year. The acquisition price of $360 million has two components a $290 million upfront payment and a $70 million milestone-based payment.

After the takeover, the Lonza facility will be merged with Genentech Singapore's existing facility....

To continue reading, please login or register for free

Click for more on: roche | lonza | genentech | avastin | singapore | finance | asia

Print Edition

FinanceAsia Print Edition

CONFERENCES